Member Info for Energyshares

£200 ex China will be the price of a banquet in our Chippy soon.
Bloody inflation….

Avacta want to keep lead precision AVA6000 in house.

But at present they don’t have the cash to take this through full trials and to market.

AVA3996 would this licence deal be enough to see out their vision.

Do we take on a partner on AVA6K on a 50/50 deal where they pay for trials and take to market and Avacta retain 50%.

If AVA6000 data is remarkable this then lowers the risk substantially on the main Jewel in the crown.
TMac

Affimers & Precision
That’s what Big Pharma will be fighting for.

Look at Commercial Advantages of Affimers
• Proprietary and unencumbered IP.
• Freedom to operate where there is antibody IPR.
• Security of supply.
• Cheaper to produce (E.coli)

GLA

David Wilson talking to David Fraser From BBI on Linkedin about him missing AACC in Chicago.
“See you at Medica then”

Medica 14th to 17th November 2022 Dusseldorf, germany

David Wilson is getting around a lot of these diagnostic conferences let’s hope for news on a new Avacta diagnostic test.

Thanks gmcc

Thanks for info Hanoik

Now I can’t get my head around this:
Deal with Tufts & Point on Canseek to include PNT2004, a pan tumor treatment.

PNT2004 just about to start phase 1 trial Pre clinical done.

https://www.pointbiopharma.com/our-products/pipeline

TORONTO and BOSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT) today announced that it has entered into a definitive agreement with Bach Biosciences, a company commercializing the research of William Bachovchin, Professor of Developmental, Chemical and Molecular Biology at Tufts University School of Medicine, Boston. The agreement provides POINT the exclusive global rights to commercialize the groundbreaking canSEEK™ tumor targeting technology.
With canSEEK™, POINT expands its theragnostic oncology pipeline to include PNT2004, a pan tumor treatment. By seeking out highly expressed markers found in many tumors but not found in healthy tissue, canSEEK™ is a promising technology for use in next generation radiopharmaceuticals, as it may allow for the precision treatment of a variety of solid tumor cancers.

But no mention of Avacta.
But their statement on pipeline:

POINT’s CanSEEK™ has been sub-licensed from both Bach Biosciences and Avacta,?which has branded the technology as pre | CISION (an Avacta trademark)??mCRPC = Metastatic Castration Resistant Prostate Cancer, PSMA = Prostate Specific Membrane Antigen, SSTR = somatostatin receptors, FAP-a = Fibrolast Activation Protein -a

https://www.investegate.co.uk/point-biopharma/gnw/point-biopharma-and-bach-biosciences-announce-licensing-and-partnership-for-canseek--8482--pan-cancer-targeting-technology/20201110120000H2315/

Does anyone know if this is a separate deal with Tufts?

Check out this link explaining radioligands

Radioligands work like cancer-seeking missiles

https://radioligands.org/

Now add on precision chemistry very similar to TMac

We continue to receive significant commercial interest in the TMAC concept, so I am delighted that we have been able to demonstrate superior efficacy and targeting of the warhead to the tumour with the first TMAC that we have tested in animals.

Both sending missiles ( warheads ) to the tumour.

https://avacta.com/successful-initial-proof-of-concept-for-a-proprietary-new-class-of-anti-cancer-therapy/

Look at the pipe line
2 targets showing so far
https://www.pointbiopharma.com/our-products/pipeline

Neut

“a royalty on sales of FAP-activated radiopharmaceuticals by POINT and a percentage of any sublicensing income received by POINT.”

Fard
Look at Points pipeline
Canseek is also precision they have targets sitting waiting for phase 1 to start just waiting on data release.

They have had access to data throughout trial and I think they know what’s coming that’s why they have can seek sitting on their pipeline list.
Waiting for AS to release the data.

They are at least 12 months ahead of AVA3996 and would move a lot faster than AVA6000.

https://www.pointbiopharma.com/our-products/pipeline

https://avacta.com/license-agreement-with-point-biopharma-inc/

Everyone waiting on a licence for AVA3996 but we are way further ahead with Point Bio.
After the data is released and positive as we hope.
Point Bio could probably get these radiopharmaceutical prodrugs to market quicker than Avacta could get AVA6000 to market.

A lot of royalties & milestone payments coming Avacta’s way.

Under the terms of the agreement, Avacta will receive an upfront fee and development milestones for the first radiopharmaceutical prodrug totalling $9.5 million. Avacta will also receive milestone payments for subsequent radiopharmaceutical prodrugs of up to $8 million each, a royalty on sales of FAP-activated radiopharmaceuticals by POINT and a percentage of any sublicensing income received by POINT.

Pedro good for you.
I had a look but it’s dominated by a couple of people and another fella asking for a poll every few hours how many shares you got….
Not for me.

Gmcc & wiggly glad you both are still here and have not followed the sheep to the Teleland.

Great research,It’s been quite pleasant here today just 2 silly posts Derek and Mr A both taken down by LSE.

Looks like LSE getting the message.
GLA

Of the current senior Avacta board members,
3 have worked at GSK
Paul Fry
Eliot Forster
Fiona McLaughlin

And 3 have worked at Pfizer
Christina Coughlin
Eliot Forster
Neil Bell

Now the circles these top executives move in GSK and Pfizer will have Avacta on their radar.

And just another coincidence :

Christophe Weber has been serving as President, Chief Executive Officer and Representative Director in Takeda Pharmaceutical Company Limited since April 1, 2015. He used to work for GlaxoSmithKline.

Avacta’s board has a lot board members with Glaxo history.

They will know about Avacta.

GLA

What’s the chances of a nice RNS on Thursday to mark a year complete.

Let’s hope we hit £1.20’s by end of week.

https://www.vice.com/amp/en/article/jgqqv8/five-reasons-you-should-delete-telegram-from-your-phone

Neil Bell

“We are working with the premier UK oncology phase 1 sites”

And a few days from a year completed.

GLA

Big Al
With the data RNS
https://m.youtube.com/watch?v=ZwbQNL7E0E0

Just look at Avacta’s language from first dosed patient to second dose escalation.
Even the market size forecast has nearly doubled and reduced by 3 years.

11 August 2021

Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase 1 Clinical Trial

"If the study shows that the pre|CISIONTM technology is effective in reducing systemic toxicity of Doxorubicin in humans, then that would open up an extensive and proprietary pipeline for Avacta of next-generation pre|CISIONTM pro-drug chemotherapies with significant clinical and commercial advantages in a chemotherapy market that is expected to exceed $74 billion by 2027."

Wed, 29th Jun 2022

Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin.

AVA6000 is a novel form of doxorubicin that has been modified with Avacta's pre|CISION™ FAP-activated delivery platform to improve its safety and therapeutic index. AVA6000 has been designed to limit cell penetration of the drug, and therefore its cell killing effect, until it is specifically activated by fibroblast activation protein a (FAP) which is in high concentration in many solid tumours compared with healthy tissues. The resulting reduced exposure of healthy tissues to active doxorubicin has the potential to significantly increase its therapeutic index by reducing the incidence of adverse effects, including cardiotoxicity and myelosuppression. Anthracyclines such as doxorubicin, a generic chemotherapeutic agent, with a market size that is expected to grow to $1.38bn by 2024

USA big Pharma sitting on some war chest from covid vaccines cash.
And you can buy a lot more GBP to the dollar in the last year.

I think if we get the read out we are all expecting, one of the big USA Pharma will pounce.

GLA